PeptidePedia The community reference

Vial filling and stoppering (revision 18)

Old revision·18:26, 14 Aug 2025·MolarMassMaeve

This is an old revision of this page, as it stood at 18:26, 14 Aug 2025, saved by MolarMassMaeve with the summary correct the freezer temperature range given for long-term storage. It may differ substantially from the current revision, and any error it contains may since have been corrected.
Vial filling and stopperingFill and finish
cakeheadspacecrimp5 mg
DeterminesFill mass, headspace, container integrity
Sequence for lyophilisateFill, partially stopper, dry, seat, cap
Failure mode of interestUnderfill; seal defects
Analytical method infobox · conventions

Vial filling and stoppering is the operation that transfers material into its final container and closes it. For a lyophilised product the sequence is distinctive: solution is filled, stoppers are seated only partially so that vapour can escape, the vials are dried in the chamber, and the stoppers are then pressed home before the vials leave it.[1]

Two attributes are set here and nowhere else. Fill mass determines how much material a purchaser receives — see Underfilling — and container closure integrity determines whether the contents stay dry and uncontaminated for the shelf life.[2]

Neither is visible in a chromatographic determination. A certificate reporting purity describes the material; it says nothing about how much of it is in the vial or whether the vial is sealed.[3]

Fill control

[edit]

Filling is volumetric or gravimetric. Volumetric filling meters a volume and relies on solution density; gravimetric filling weighs, in-process or in a sampling plan, and is more directly connected to the quantity of interest.[1]

Fill accuracy is specified as a tolerance and monitored during the run, since pump and valve behaviour drifts, and the in-process records are part of the batch documentation.[4] A deliberate overage above the label claim is ordinary and compensates for losses in reconstitution and withdrawal; it is not a defect. See Underfilling.

For a peptide the mass of interest is peptide mass, which is fill mass multiplied by content. A fill process controlled to a tight tolerance on solid mass still delivers a variable peptide mass if content varies between lots, which is why content belongs on the certificate alongside purity.[3]

Stoppering and seal integrity

[edit]

The stopper is an elastomeric closure that must reseal after needle penetration, not shed particles, and not interact with the contents. For lyophilised products it is seated in two stages, since the partially seated position is what allows water vapour to leave during drying.[1]

An aluminium seal is crimped over the stopper to hold it in place. A loose crimp, a stopper that has lifted, or a cracked flange are the visible defects; container closure integrity is formally established by test rather than by inspection.[2]

ObservableWhat it may indicate
Loose or spinning crimpIncomplete seating
Lifted stopperVacuum lost, or drying incomplete
Cracked flangeHandling or transport damage
Cake collapse or discolourationDrying or storage problem, not sealing

These are handling observations, not determinations. None establishes that contents are compromised, and their absence does not establish integrity — which is the general shape of every visual check on this wiki.[2]

Headspace

[edit]

Lyophilised products are commonly stoppered under partial vacuum or under an inert gas. Vacuum stoppering gives a check that is available to a purchaser — a vial under vacuum draws air in audibly when first vented — while inert-gas stoppering does not.[1]

Headspace composition affects oxidative degradation. A vial stoppered under nitrogen exposes its contents to far less oxygen than one stoppered under air, which matters for sequences containing methionine. See Methionine oxidation.

See also

References

  1. ^ a b c d International Council for Harmonisation, Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients (2000).
  2. ^ a b c United States Pharmacopeia, General Chapter <1207>, Package Integrity Evaluation — Sterile Products.
  3. ^ a b United States Pharmacopeia, General Chapter <1503>, Quality Attributes of Synthetic Peptide Drug Substances.
  4. ^ ISO 9001:2015, Quality management systems — Requirements.